This page shows you your search results in order of relevance. This is page number 4.
Order by Relevance | Date
Total 4468809 results found since Jan 2013.
A new liposomal nanocarrier for co-delivery of gedunin and p-glycoprotein siRNA to target breast cancer stem cells
Nat Prod Res. 2022 Jan 27:1-4. doi: 10.1080/14786419.2022.2032048. Online ahead of print.ABSTRACTGedunin is a secondary metabolite found in neem tree. Since the first discovery of this compound, its bio-active properties have been continuously evaluated. However, the low hydrophobicity of gedunin decreases its bioavailability and pharmacokinetic profile. In the present investigation, a new liposomal nanocarrier for co-delivery of gedunin and P-glycoprotein (P-gp) siRNA [siRNA coated liposomal gedunin (Lipo-Ged-siRNA)] was developed to improve the anti-proliferative activity of gedunin. Characteristics of prepared Lipo-Ged-...
Source: Natural Product Research - January 27, 2022 Category: Biochemistry Authors: Mohan Singh Rana Meran Keshawa Ediriweera Umapriyatharshini Rajagopalan Desiree Nedra Karunaratne Kamani Hemamala Tennekoon Sameera Ranganath Samarakoon Source Type: research
VCAM-1-binding peptide targeted cationic liposomes containing NLRP3 siRNA to modulate LDL transcytosis as a novel therapy for experimental atherosclerosis
CONCLUSION: These findings established a novel strategy for targeting the NLRP3 inflammasome using NLRP3 siRNA-PCLs to interrupt LDL transcytosis, representing a potential novel therapy for atherosclerosis.PMID:35917895 | DOI:10.1016/j.metabol.2022.155274
Source: Atherosclerosis - August 2, 2022 Category: Cardiology Authors: Xiong Jia Xiangli Bai Xiaoyan Yang Ling Wang Yajing Lu Lin Zhu Ying Zhao Wenzhuo Cheng Meng Shu Qiyong Mei Si Jin Source Type: research
Tumor-specific delivery of siRNA using supramolecular assembly of hyaluronic acid nanoparticles and 2b RNA-binding protein/siRNA complexes.
Abstract
Anticancer therapeutics delivering exogenous siRNA have been explored to suppress the tumor-associated genes, but several limitations of siRNA delivery such as tumor-targeted delivery, controlled siRNA release at the sites of interest, or instabilities of siRNA in physiological fluids should be preferentially addressed for its clinical applications. As an attempt to meet these criteria, we designed a supramolecular assembly, which was composed of cholesterol-bearing hyaluronic acid (HA-Chol) conjugates and 2b RNA-binding protein (2b)/siRNA complexes. In contrast to the traditional siRNA polyplexes using e...
Source: Biomaterials - May 19, 2014 Category: Materials Science Authors: Choi KM, Jang M, Kim JH, Ahn HJ Tags: Biomaterials Source Type: research
Effects of sterol derivatives in cationic liposomes on biodistribution and gene-knockdown in the lungs of mice systemically injected with siRNA lipoplexes
Mol Med Rep. 2021 Aug;24(2):598. doi: 10.3892/mmr.2021.12237. Epub 2021 Jun 24.ABSTRACTCationic liposomes can be intravenously injected to deliver short interfering (si)RNAs into the lungs. The present study investigated the effects of sterol derivatives in systemically injected siRNA/cationic liposome complexes (siRNA lipoplexes) on gene‑knockdown in the lungs of mice. Cationic liposomes composed of 1,2‑dioleoyl‑3‑trimethylammonium‑propane or dimethyldioctadecylammonium bromide (DDAB) were prepared as a cationic lipid, with sterol derivatives such as cholesterol (Chol), β‑sitosterol, ergosterol (Ergo) or stig...
Source: Molecular Medicine - June 24, 2021 Category: Molecular Biology Authors: Yoshiyuki Hattori Hiromu Saito Teruaki Oku Kei-Ichi Ozaki Source Type: research
siRNA-Based Novel Therapeutic Strategies to Improve Effectiveness of Antivirals: An Insight
AAPS PharmSciTech. 2023 Aug 11;24(6):170. doi: 10.1208/s12249-023-02629-1.ABSTRACTSince the ground-breaking discovery of RNA interference (RNAi), scientists have made significant progress in the field of small interfering RNA (siRNA) treatments. Due to severe barriers to the therapeutic application of siRNA, nanoparticle technologies for siRNA delivery have been designed. For pathological circumstances such as viral infection, toxic RNA abnormalities, malignancies, and hereditary diseases, siRNAs are potential therapeutic agents. However, systemic administration of siRNAs in vivo remains a substantial issue due to a lack o...
Source: AAPS PharmSciTech - August 11, 2023 Category: Drugs & Pharmacology Authors: Krittika Chatterjee Sagheerah Lakdawala Sheikh Shahnawaz Quadir Dinesh Puri Dinesh Kumar Mishra Garima Joshi Sanjay Sharma Deepak Choudhary Source Type: research
i-Fect™ Delivers Your siRNA Payload
Delivering siRNA to Dorsal Root Ganglia to Silence KV Receptors.Our i-Fect transfection kits continue to be used to optimize delivery in vivo and into hard to transfect cells like primary neurons. In these 2 latest expamples, researchers use i-Fect to deliver siRNA to KV Receptors in Rat DRGs. Knocking down these receptors enable the study of their role in pain modulation: John H. Winston, Sushil K. Sarna. Developmental Origins of Functional Dyspepsia-Like Gastric Hypersensitivity in Rats. Gastroenterology. Volume 144, Issue 3, March 2013, Pages 570–579.e3. dx.doi.org/10.1053/j.gastro.2012.11.001....intrathecal treatment...
Source: Neuromics - March 16, 2013 Category: Neuroscience Tags: siRNA delivery in-vivo Delivering siRNA to the CNS KV receptors. i-Fect Kv9.1 Potassium Channel Source Type: news
Core-Shell type lipid/rPAA-Chol polymer hybrid nanoparticles for in vivo siRNA delivery.
In this study, the core-shell type lipid/rPAA-Chol hybrid nanoparticles (PEG-LP/siRNA NPs and T7-LP/siRNA NPs) were developed for improving in vivo siRNA delivery by modifying the surface of rPAA-Chol/siRNA nanoplex core with a lipid shell, followed by post-insertion of polyethylene glycol phospholipid (DSPE-PEG) and/or peptide (HAIYPRH, named as T7) modified DSPE-PEG-T7. The integrative hybrid nanostructures of LP/siRNA NPs were evidenced by dynamic light scattering (DLS), confocal laser scanning microscope (CLSM), cryo-transmission electron microscope (Cryo-TEM) and surface plasmon resonance (SPR) assay. It was demonstr...
Source: Biomaterials - December 5, 2013 Category: Materials Science Authors: Gao LY, Liu XY, Chen CJ, Wang JC, Feng Q, Yu MZ, Ma XF, Pei XW, Niu YJ, Qiu C, Pang WH, Zhang Q Tags: Biomaterials Source Type: research
SiRNA-phospholipid conjugates for gene and drug delivery in cancer treatment.
In this study, the thiol-modified sense and antisense siRNA are chemically conjugated with phospholipids to form sense and antisense siRNA-phospholipid, and then these sense or antisense siRNA-phospholipids with equal amounts are annealed to generate siRNA-phospholipids. The siRNA-phospholipids can serve dual functions as agents that can silence gene expression and as a component of nanoparticles to embed hydrophobic anticancer drugs to cure tumor. siRNA-phospholipids together with cationic lipids and DSPE-PEG2000 fuse around PLGA to form siRNA-phospholipids enveloped nanoparticles (siRNA-PCNPs), which can deliver siRNAs a...
Source: Biomaterials - May 2, 2014 Category: Materials Science Authors: Liu H, Li Y, Mozhi A, Zhang L, Liu Y, Xu X, Xing J, Liang X, Ma G, Yang J, Zhang X Tags: Biomaterials Source Type: research
A New Approach of Delivering siRNA to the Cornea and its Application for Inhibiting Herpes Simplex Keratitis.
Abstract
Small interfering RNA (siRNA) is a potential agent for the treatment of ocular surface diseases. Previous studies delivered siRNA by directly injecting siRNA into cornea or conjunctiva. In the present study we sought to explore an alternative approach to deliver siRNA into mouse cornea via eye drops that contains cy3-labeled siRNA (cy3-siRNA) and different cationic complexing agents and to evaluate the effects of siRNA targeting HSV-1 ICP4 gene (ICP4-siRNA) on mouse herpes simplex keratitis (HSK). Cy3-siRNA was mixed with Lipofectamine 2000, EntransterTM-in vivo, polyethyleneimine (PEI) or PEO-PPO-PEO pol...
Source: Current Molecular Medicine - October 21, 2014 Category: Molecular Biology Authors: Li Z, Duan F, Lin L, Huang Q, Wu K Tags: Curr Mol Med Source Type: research
Co-delivery of Doxorubicin and Bmi1 siRNA by Folate Receptor Targeted Liposomes Exhibits Enhanced Anti-Tumor Effects in vitro and in vivo
Bmi1 gene overexpression is found in various human tumors and has been shown as a potential target for gene treatment. However, siRNA-based treatments targeting Bmi1 gene have been restricted to limited delivery, low bioavailability and hence relatively reduced efficacy. To overcome these barriers, we developed a folate receptor targeted co-delivery system folate-doxorubicin/Bmi1 siRNA liposome (FA-DOX/siRNA-L). The FA-DOX/siRNA-L was prepared through electrostatic interaction between folate doxorubicin liposome (FA-DOX-L) and Bmi1 siRNA. In vitro and in vivo studies showed that FA-DOX/siRNA-L inhibited tumor growth by com...
Source: Theranostics - November 15, 2014 Category: Molecular Biology Authors: Tan Yang, Bin Li, Shibo Qi, Yong Liu, Yongkang Gai, Peng Ye, Guang Yang, Wendian Zhang, Peng Zhang, Xingxing He, Weijie Li, Zhiping Zhang, Guangya Xiang, Chuanrui Xu Tags: Research Paper Source Type: research
